Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
Study sponsor: Arcutis Biotherapeutics, Inc. · ARQT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-04-06Actual
Enrollment · participants457Actual
Source updated2024-03-12Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.